An inspirational East Kilbride teenager studying to become a nurse is living proof that trials of new treatments for children with cancer can save lives.
Katie Currie was just three years old when diagnosed with acute lymphoblastic leukaemia.
Her parents Neil and Siobhan said they felt like their world came crashing down, as months of treatment began.
Then two years later in 2008, aged five, Katie relapsed.
The Lanarkshire Live app is available to download now.
Get all the news from your area as well as features, entertainment, sport and the latest on Lanarkshires recovery from the coronavirus pandemic straight to your fingertips, 24/7.
The free download features the latest breaking news and exclusive stories, and allows you to customise your page to the sections that matter most to you.
Head to the App Store and never miss a beat in Lanarkshire - iOS - Android
After a nationwide search for a donor whose stem cells were a match - a campaign supported by the East Kilbride News at the time - she had a stem cell transplant on September 11, 2008.
Katie began a clinical trial that Cancer Research UK helped fund for a new chemotherapy treatment called mitoxantrone, and the trial results were striking.
Mitoxantrone proved so effective that all children taking part in the trial were put on the new chemotherapy drug as soon as possible.
Now Katie, who is in remission, is sharing her remarkable story to support Childhood Cancer Awareness Month this September.
She is passionate about giving back after the treatment shes received, and that starts with studying for a degree in child health nursing at Edinburgh Napier University.
Katie, 19, said: I am living proof that clinical trials work and feel proud I took part in a trial that helped change in a positive way how some childhood cancers are treated.
I was so young when I was diagnosed that I dont remember much from then, but I do remember being in hospital and I remember the nurses.
It is surreal to think about what I went through then and how far I have come. Now Im keen to do everything I can to put something back and help the NHS.
Cancer Research UK funded scientists helped show that the drug mitoxantrone can increase survival by more than 50 per cent in children whose acute lymphoblastic leukaemia has come back after treatment.
Katie is one of around 330 young people up to the age of 25 who are diagnosed with cancer in Scotland every year.
Acute lymphoblastic leukaemia (ALL), a cancer of the white blood cells has a particularly high survival rate. Thanks to major advances in treatment, more than nine in 10 children in the UK with ALL now survive for at least five years, compared with around seven in 10 in the 1980s.
Professor Vaska Saha, based at the University of Manchester, was researching ways to improve treatment options for children like Katie Currie who were facing leukaemia for a second time and led research on mitoxantrone.
The drug works by jamming a molecule in cancer cells responsible for untwisting DNA. Blocking this process literally ties the cells DNA up in knots so it cant grow and multiply. It also works on cancer cells that have resisted previous treatment- even if theyre hidden among healthy cells.
Professor Saha was part of an international team working on the clinical trial, known as ALLR3, comparing the drug idarubicin, a chemotherapy treatment normally used for young people whose leukaemia had relapsed to mitoxantrone, which had proved successful in early trials in the lab.
A total of 216 children and young people including Katie took part in the trial. They were split in to two groups. One group was given the drug idarubicin and the other group mitoxantrone.
The study evaluated the number of children whose leukaemia hadnt got worse over the three years since treatment.
Results showed that just over six out of 10 children (64.6 per cent) who had mitoxantrone, compared to less than four out of 10 children (35.9 per cent) who had idarubicin, had cancers that hadnt grown at all in the timeframe.
The study also found that the number of children alive three years after treatment, regardless of whether their cancer had grown or not, was far higher in the group on mitoxantrone compared to idarubicin. This is known as overall survival.
The trial had been planned to continue for several years. But it was halted early and all the children who had originally been given idarubicin were transferred to mitoxantrone.
Professor Saha said: A difference in outcomes like that had never been reported before. It took all of us by surprise.
Now Katie is packing her bags this September to head off to her second year at university studying nursing. Her parents are hugely proud of everything shes achieved but they recall vividly the early years when life seemed less positive.
Dad Neil said: When Katie was first diagnosed and started treatment in Glasgow, we put our trust in the doctors at the hospital.
We took it day by day, especially after she relapsed. When the cancer came back, you fear everything, but we spoke to the team about the trial and put complete faith in them.
Mum Siobhan said: We believed that, with the clinical trial Katie had the best chance of recovery. Without these trials, amazing new treatments may never be found. Mitoxantrone probably saved Katies life.
Katie, who has some side-effects from her experience including endocrine issues and the loss of vision in one eye after she developed CMV retinitis, has annual check-ups now.
Katie said: I have just had the first set of these check-ups in the adult services department, as they had been in the childrens unit before.
I felt anxious going but the doctor that treated me was still there for the checks, so that definitely helped. It is still scary though, as you dont know what they are going to say and it was a huge relief that everything was ok.
She said she always knew she wanted to be involved in healthcare, adding: "I knew I wanted to do something in medicine after what had happened to me, and I was interested in being a paramedic too but it changed over the years. By doing this, I really want to say thank you for the help I had and I am passionate about nursing.
I started uni in Sept 2021 and I still had to be shielded a bit, but I really enjoyed the course and I am just starting the second year now. I have been on two placements already and I think that my own experience has really helped me with my understanding with patients.
The course is three years long and then I can choose where I focus on. I am just so pleased to be able to do this after my experience and to give back for the help I had.
Dad Neil said the whole family including Katies sister Libby, 17, are proud of Katie.
He said: Katie has been through so much but she is resilient and so upbeat in all that she does. She just gets on with things and is so kind too.
At an early age, she talked about being involved in medicine and we did ask if she was sure she wanted to go into that after all she had experienced, but she was adamant.
Thinking back to those days of Katies treatment and relapse when she was so young, it is just amazing to be here now and for her to be off to Edinburgh following her dreams.
"Back then, we put our faith in the research and everything that goes on behind the scenes. That has been incredible for us and for Katie, but we know there is more that still needs to be done to make treatments more effective and kinder too, so that there are less side-effects.
"We know how important this work is for children in the future and thats why we support Cancer Research UK and all the research that needs to be funded.
Cancer Research UK celebrates its 20th anniversary in 2022. However, its history dates back to the founding of the Imperial Cancer Research Fund in 1902.
Thanks in part to the charitys work, childrens cancer survival in the UK has more than doubled since the 1970s when just over a third of children diagnosed survived beyond ten years. Today, its around 8 in 10 but theres still much further to go.
Cancer Research UK spokeswoman in Scotland, Lisa Adams, said: Were grateful to Katie and her family for their support.
Cancer in children and young people is different to cancer in adults- from the types of cancer to the impact of treatments and the long-term side effects survivors often experience.
Supporters can help by wearing a gold ribbon badge the awareness symbol of Childhood Cancer Awareness Month available from Cancer Research UK shops and selected TK Maxx stores during September.
Find out more here.
Don't miss the latest headlines from around Lanarkshire. Sign up to our newsletters here.
And did yo u know Lanarkshire Live is on Facebook? Head over to our page to give us a like and share.
Read more from the original source:
Courageous Lanarkshire teen who survived leukaemia thanks to a clinical trial pursues nursing dream - Daily Record
- Cell-Based Regenerative Medicine Market Size to Witness Rapid Growth at a CAGR of 15% by 2032 | insightSLICE - EIN News - May 9th, 2023
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 21st, 2023
- Cell culture - Wikipedia - December 18th, 2022
- The Legacy of Henrietta Lacks - Hopkins Medicine - December 10th, 2022
- HOME | Stem cell & Cancer - October 4th, 2022
- CAR T Cell Therapy Offers a New Hope in the Treatment of Severe and Refractory Systemic Lupus Erythematosus - Rheumatology Network - October 4th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 4th, 2022
- Outlook on the Automated Cell Counters Global Market to 2028 - Use of Cell Counters in Personalized Medicine Presents Opportunities -... - October 4th, 2022
- Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - BioPharm International - October 4th, 2022
- Breakthrough in production of cancer-treating drug - Stanford University News - October 4th, 2022
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 4th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 4th, 2022
- 5 FDA decisions to watch in the fourth quarter - BioPharma Dive - October 4th, 2022
- bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease -... - October 4th, 2022
- Laser Focus World highlights UC research that uses light to restore cell function - University of Cincinnati - October 4th, 2022
- The Institute of Regenerative Medicine | Non-Surgical, Cell-Based ... - September 25th, 2022
- CAR T-Cell Therapy Shows Promise in Treating Lupus - Healthline - September 25th, 2022
- ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit - El Paso Inc. - September 25th, 2022
- Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit - GlobeNewswire - September 25th, 2022
- Alzheimer's disease risk linked to newly discovered protein mutation - Medical News Today - September 25th, 2022
- Biological Links Identified Between an Aggressive Breast Cancer Type and African Ancestry - Weill Cornell Medicine Newsroom - September 25th, 2022
- The Use of Nanorobotics in the Treatment Therapy of Cancer and Its Future Aspects: A Review - Cureus - September 25th, 2022
- UW Health, UW-Madison School of Medicine and Public Health: Innovative clinical trial targets recurrent BK infection in kidney transplant recipients -... - September 25th, 2022
- Shutting down backup genes leads to cancer remission in mice - University of Michigan News - September 25th, 2022
- Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges... - September 25th, 2022
- FDA's ODAC Votes That Benefits Do Not Outweigh Risks for Poziotinib in HER Exon 20 Ins+ NSCLC - Targeted Oncology - September 25th, 2022
- Discovery Reveals How the Immune System Tolerates Friendly Gut Bacteria - Weill Cornell Medicine Newsroom - September 8th, 2022
- Study: New Factors Are Associated With Increased PFS from BCMA-Targeted T-Cell Therapy - Pharmacy Times - September 8th, 2022
- Study Uncovers Possible Path for Improving T Cell Therapies - University of Arizona - September 8th, 2022
- Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study - Gilead Sciences - September 8th, 2022
- Manipulating Astrocytes in Tumor Environment Effective Against Glioblastoma - Inside Precision Medicine - September 8th, 2022
- Jane Fonda Diagnosed with Non-Hodgkin's Lymphoma: What to Know - Healthline - September 8th, 2022
- Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC - AJMC.com Managed Markets Network - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- The Role of Eosinophils as a Biomarker to Inform Treatment Decisions for Patients With COPD - Consultant360 - August 30th, 2022
- Scientists Discover Surprise Anticancer Properties of Common Lab Molecule | Newsroom - UNC Health and UNC School of Medicine - August 30th, 2022
- Overall survival is similar for patients receiving CT-based or minimal follow-up after surgical resection of non-small-cell lung cancer - 2 Minute... - August 30th, 2022
- NSF Grant to Aid OSU Researchers Developing Treatment for Canine Cancer - The Corvallis Advocate - August 30th, 2022
- Researchers Identify the Target of Immune Attacks on Liver Cells in Metabolic Disorders - Weill Cornell Medicine Newsroom - August 22nd, 2022
- Why Is CAR T-Cell Therapy One of the Most Phenomenal Advances in Science? - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms - PR Newswire - August 22nd, 2022
- Cell Analysis Global Market Report 2022: Growing Focus on Personalized Medicine & Introduction of Advanced Technologies in Cell Analysis Presents... - August 22nd, 2022
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 22nd, 2022
- Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimers Disease Patients, Findings Published in Science Translational Medicine - BioSpace - August 22nd, 2022
- Restoring cell and organ function after the heart stops - National Institutes of Health (.gov) - August 22nd, 2022
- Rolling the Dice: Gamble Pays Off For Cancer Patient in CAR T-Cell Clinical Trial - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Boosting neuron formation restores memory in mice with Alzheimer's disease - EurekAlert - August 22nd, 2022
- UTSW study finds p53 gene plays second role in suppressing genes tied to cancer - UT Southwestern - August 22nd, 2022
- GlyNAC supplementation reverses mitochondrial dysfunction, oxidative stress and aging hallmarks to boost strength and promote health in aging humans -... - August 22nd, 2022
- Multiple shots of the BCG vaccine protect type 1 diabetics from COVID-19 - EurekAlert - August 22nd, 2022
- Cell Regeneration Medicine Market Analysis by Type, Application, Growth, Demand, Status, and Forecast from 2022 to 2032 - Digital Journal - August 5th, 2022
- Higher Hydroxyurea Exposure Tied to Better Blood Parameters in US... - Sickle Cell Anemia News - August 5th, 2022
- Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here - Newshub - July 27th, 2022
- MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug - PMLiVE - July 27th, 2022
- CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure' - Medscape - July 27th, 2022
- Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated... - July 27th, 2022
- CRISPR therapeutics can damage the genome - EurekAlert - July 27th, 2022
- To cell surface and beyond: Tracing subcellular glycoprotein transport using modified cholera toxin - EurekAlert - July 27th, 2022
- From Donor to Patient: Advancing the Future of Cell Therapies - Genetic Engineering & Biotechnology News - July 27th, 2022
- Five-Year Review of Biomedical Research Imaging Center, Center Director | Newsroom - UNC Health and UNC School of Medicine - July 27th, 2022
- Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer - Yale School of Medicine - July 11th, 2022
- Stem Cell Assays Market Report 2022-2027: Increasing Awareness About Therapeutic Potency of Stem Cells Driving Growth - ResearchAndMarkets.com -... - July 11th, 2022
- Sickle cell disease could be treated with common plant, study finds - The Telegraph - July 11th, 2022
- Unexpected link between most common cancer drivers may yield more effective drugs - University of Wisconsin-Madison - July 11th, 2022
- Scientists Discover Key to Hepatitis A Virus Replication, Show Drug Effectiveness | Newsroom - UNC Health and UNC School of Medicine - July 11th, 2022
- How Erectile Dysfunction Drugs Can Help Treat Cancer and Save Thousands of Lives - SciTechDaily - July 11th, 2022
- Pune: Dr Mohan Wani appointed as director of National Centre for Cell Science - The Indian Express - July 11th, 2022
- Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma - Gilead... - July 3rd, 2022
- Important Factors for Regulating the Body's Immune Response - Neuroscience News - July 3rd, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - July 3rd, 2022
- Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with... - July 3rd, 2022
- Growing scope of Genetic Medicine and Stem Cell Research - The Hindu - June 22nd, 2022
- When children with sickle cell grow up, they face a system not designed for them - 89.3 WFPL News Louisville - June 22nd, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 22nd, 2022
- Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - June 22nd, 2022
- Bringing heart and humanity to hematology | News | Harvard TH Chan School of Public Health - HSPH News - June 22nd, 2022
- Belzutifan Improves Survival in Patients With RCC and VHL - Targeted Oncology - June 22nd, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 13th, 2022
- ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy - BioPharma Dive - June 13th, 2022